New Guidelines for RSV Vaccination
Every fall, influenza and RSV (respiratory syncytial virus) capture headlines. If you’re not already familiar, RSV is a highly contagious virus that can cause respiratory infections and is the most frequent cause of lower respiratory tract illness in infants across the globe.
While most people with RSV have more mild, cold-like symptoms, some develop serious infections, including pneumonia and bronchiolitis, that require hospitalization. In fact, infants and children are at the greatest risk of developing serious RSV and it is the leading cause of infant hospitalization in the United States, according to the CDC, which is why a new vaccine for pregnant women is especially welcome.
In August, the FDA approved the first-ever RSV vaccine, known as Abrysvo, for use during pregnancy to protect newborns in their first six months after birth. The vaccine is designed to be administered as a single dose during 32-36 weeks of gestation during RSV season—typically September through January.
“We are thrilled to be able to offer an RSV vaccine during pregnancy for the first time and to help protect newborns when they are most vulnerable,” said Nurse Practitioner Elise Pesch. “If you have questions about RSV, vaccines or anything else during your pregnancy, we are always happy to listen, share the latest research and support you during this time.”
Reported side effects for the vaccine include pain at injection site, muscle pain, headache and nausea.
